4 recruiting, 3 completed, 2 not yet recruiting, 1 suspended. 5 Phase 2, 3 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Secondary Progressive Multiple Sclerosis (SPMS): new trials by email Literature Review of Secondary Progressive Multiple Sclerosis (SPMS) trials Research Report on Secondary Progressive Multiple Sclerosis (SPMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis. Online wellness course and online exercise platform, Usual Care Group - Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS) | Not applicable | Not yet recruiting | University of Iowa | 118 | 2026-11-15 | 2026-09-28 |
| A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) SUN-627, Placebo - Primary Progressive Multiple Sclerosis, Primary Progressive MS | Phase 2 | Recruiting | Sundance Biosciences, Inc. | 20 | 2026-10-01 | 2026-09-25 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Remibrutinib (blinded), Placebo, Remibrutinib (Open label) - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 1275 | 2025-11-11 | 2026-10-13 |
| Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis NG01 - Autologous bone marrow derived human stromal cells, Sodium Chloride 0.9% - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 2 | Not yet recruiting | NeuroGenesis Ltd. | 45 | 2025-10-01 | 2025-05-07 |
| The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis Rituximab, Saline (NaCl 0,9 %) (placebo) - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 2 | Recruiting | Cairo University | 46 | 2024-08-01 | 2026-03-18 |
| Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS SCM-010 - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Withdrawn | Stem Cell Medicine Ltd. | 2024-02-01 | 2024-04-18 | |
| Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients Mayzent - Secondary Progressive Multiple Sclerosis (SPMS) | Completed | Novartis Pharmaceuticals | 451 | 2020-10-28 | 2024-02-12 | |
| Multiple Sclerosis-Simvastatin Trial 2 Simvastatin, Placebo - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | Completed | University College, London | 964 | 2018-03-28 | 2024-09-19 |
| Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors Interferon beta-1b (Betaseron, BAY86-5046) - Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) | Completed | Bayer | 10 | 2007-08-01 | 2012-11-01 |
Multiple Sclerosis, Chronic Progressive (11) · Multiple Sclerosis (6) · Demyelinating Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Fatigue (1) · Immune System Diseases (1) · Motor Activity (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1)
Chronic Disease (11) · Disease Attributes (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Autoimmune Diseases (10) · Autoimmune Diseases of the Nervous System (10) · Demyelinating Autoimmune Diseases, CNS (10) · Immune System Diseases (10) · Nervous System Diseases (10) · Demyelinating Diseases (9) · Multiple Sclerosis (5) · Behavior (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Inflammation (1)
Sodium Chloride (2) · Bendamustine Hydrochloride (1) · Cyclophosphamide (1) · Interferon beta-1b (1) · Interleukin-2 (1) · Mesna (1) · Rituximab (1) · Simvastatin (1) · aldesleukin (1) · fludarabine (1) · ocrelizumab (1) · remibrutinib (1) · siponimod (1)
Novartis Pharmaceuticals (2) · Bayer (1) · Cairo University (1) · Indapta Therapeutics, INC. (1) · NeuroGenesis Ltd. (1) · Stem Cell Medicine Ltd. (1) · Sundance Biosciences, Inc. (1) · Tr1X, Inc. (1) · University College, London (1) · University of Iowa (1)
United States (6) · Israel (3) · Portugal (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Colombia (1) · Croatia (1) · Czechia (1)
Amr Hassan Elsayed, MD Neurology (1) · Arnon Karni, Dr. (1) · Jeremy Chataway (1) · Maha Atef Zaki, MD Neurology (1)
PMID 26751635, PMID 33253391, PMID 34135843, PMID 34719198, PMID 35031587, PMID 35945550, PMID 35946107, PMID 37318885, PMID 39284697, PMID 41045938
2017 (1), 2025 (1)